Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA1 | Q15788 | 2/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.39 |
| ▸ | CA2 | P00918 | 11/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA5A | P35218 | 6/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.39 |
| ▸ | CA4 | P22748 | 6/20 | 0.39 |
| ▸ | CA3 | P07451 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 5/20 | 0.39 |
| ▸ | CA7 | P43166 | 5/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22020692 | 0.85 | LMNA (0.45) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL14164240 | 0.83 | LMNA (0.44) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL33099 | 0.75 | KDM4E (0.43) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL5196234 | 0.74 | FFAR2 (0.40) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| Hydrochloric Acid SCHEMBL6706482 | 0.74 | KDM4E (0.42) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL1107386 | 0.73 | HCAR2 (0.68) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL4292895 | 0.73 | HCAR2 (0.42) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL472995 | 0.73 | CSNK2A2 (0.42) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL23388184 | 0.72 | FFAR2 (0.48) | NCOA1NCOA3LMNAPPARGNCOA2 | |
| SCHEMBL16742919 | 0.72 | FFAR2 (0.45) | NCOA1NCOA3LMNAPPARGNCOA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4561574-A1 | DOSING REGIMEN FOR A NLRP3 INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119816304-A | Dosing regimen for NLRP3 inhibitors | 诺华股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025068958-A1 | NLRP3 INHIBITOR FOR USE IN LOWERING THE RISK OF CARDIOVASCULAR DISEASES | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-20250082611-A1 | DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS | NOVARTIS AG (CH) | 2025-03-13 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079119-A1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019023147-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184624-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | NCOA1 600/4885NCOA3 483/4885LMNA 1400/4885 |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NCOA1 897/4885NCOA3 1265/4885LMNA 1347/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NCOA1 819/4885NCOA3 1048/4885LMNA 1699/4885 |
| US-20190119224-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NCOA1 926/4885NCOA3 1312/4885LMNA 1825/4885 |
| US-20250082611-A1 | DOSING REGIMEN FOR AN NLRP3 INHIBITOR IN THE TREATMENT OF OSTEOARTHRITIS | NLRP3, PYCARD, NLRP1 | NCOA1 1610/4885NCOA3 1592/4885LMNA 2301/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NCOA1 819/4885NCOA3 1048/4885LMNA 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.